91 related articles for article (PubMed ID: 27104667)
21. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
22. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
23. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
24. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
26. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
Garst J; Buller R; Lane S; Crawford J
Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
[TBL] [Abstract][Full Text] [Related]
29. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
Buechel M; McGinnis A; Vesely SK; Wade KS; Moore KN; Gunderson CC
Gynecol Oncol; 2018 Apr; 149(1):28-32. PubMed ID: 29605046
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
32. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.
Wildes TM; Ruwe AP; Fournier C; Gao F; Carson KR; Piccirillo JF; Tan B; Colditz GA
J Geriatr Oncol; 2013 Jul; 4(3):227-34. PubMed ID: 23795224
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
34. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
35. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
37. Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients.
Armbrust R; Richter R; Woopen H; Hilpert F; Harter P; Sehouli J
ESMO Open; 2021 Apr; 6(2):100081. PubMed ID: 33743329
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]